alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    Form 8-K

                     Pursuant to Section 13 or 15(d) of the
                       Securities and Exchange Act of 1934

                                 October 1, 2001
                                 Date of Report

                            RMED International, Inc.
             (Exact Name of Registrant as Specified in its Charter)

        Colorado                          0-14696                  84-0898302
(State of Incorporation)         (Commission File Number)       (I.R.S. Employer
                                                                 Identification)

                             3925 North Hastings Way
                              Eau Claire, WI 54703
                          (Address of Principal Office)

                                 (715) 831-0280
                         (Registrant's Telephone Number)

<PAGE>

Item 6. Resignation of Registrant's Directors

RMED International, Inc. ("RMED", the "Company") reports that Mr. George
Reinbacher has resigned from the Company's Board of Directors effective
September 21, 2001. Darin Pratt of Pratt Medical, one of the original founders
of the Company, has rejoined the RMED Board of Directors.


                                        2
<PAGE>

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

Date:  October 1, 2001                            RMED International, Inc.
                                                  By: /s/ Brenda Schenk
                                                  -----------------------------
                                                  Brenda Schenk, President &
                                                  Principal Financial Officer


                                        3
<PAGE>

September 21, 2001

Edward Reiss, Chairman of the Board
RMED International, Inc.
3925 N. Hastings Way
P.O. Box 188
Eau Claire, WI 54702

Dear Mr. Reiss,

Effective immediately, I resign my position as a director and board member of
RMED International, Inc.

Sincerely,

/s/ George Reinbacher
----------------------------
George Reinbacher

                                       4
§ 315.3 General factors relevant to safety and effectiveness. FDA's determination of the safety and effectiveness of a diagnostic radiopharmaceutical includes consideration of the following: ( a ) The proposed use of the diagnostic radiopharmaceutical in the practice of medicine,
( b ) The pharmacological and toxicological activity of the diagnostic radiopharmaceutical (including any carrier or ligand component of the diagnostic radiopharmaceutical), and
( c ) The estimated absorbed radiation dose of the diagnostic radiopharmaceutical.
### Summary of Analy tical Results 662 - November 2012

**Sample ID** 662-GRAB 662-GRAB 662-GRAB 662-GRAB **Date** 11/5/12 11/12/12 11/19/12 11/26/12 **Top (ft)** 0 0 0 0 **Total (T)/ Bottom (ft)**  0 0 0 0 **An aly**  **te units**  **Diss. (D) Duplicate #**  1 1 1 1 PFOA ug/L T 1.54 1.62 0.501 0.631

ug/L = micrograms per liter or parts per billion (ppb) ND = not detected (shown as <LOD) NQ = not quantifiable (shown as <LOQ) ND<LOD<NQ<LOQ LOD = limit of detection = 0.0215 ug/L LOQ = limit of quantification = 0.100 ug/L

Samples were analyzed by Critical Path Services LLC. Reported results represent a single analysis, except for the sample collected on 11/12/12. Acceptable precision was obtained and the reported result for the sample collected on 11/12/12 represents the average of lab duplicate results.

The NJDEP lab certification number for Critical Path Services LLC is PA072. PFOA = Perfluorooctanoic Acid ug/L = micrograms per Liter

< and ND = Non detect at stated reporting limit Page 1 of 1 09000064811eae88:Sheet1 2/8/2013 8:52 AM
# L_2023240EN.01010601.xml

| 28.9.2023 | EN | Official Journal of the European Union | L 240/106 |
| --- | --- | --- | --- |

28.9.2023

EN

Official Journal of the European Union

L 240/106

---

DECISION OF THE EEA JOINT COMMITTEE No 231/2020

of 11 December 2020

amending Annex XX (Environment) to the EEA Agreement [2023/2033]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

| (1) | Commission Delegated Decision (EU) 2019/708 of 15 February 2019 supplementing Directive 2003/87/EC of the European Parliament and of the Council concerning the determination of sectors and subsectors deemed at risk of carbon leakage for the period 2021 to 2030 (1) is to be incorporated into the EEA Agreement. |
| --- | --- |

(1)

Commission Delegated Decision (EU) 2019/708 of 15 February 2019 supplementing Directive 2003/87/EC of the European Parliament and of the Council concerning the determination of sectors and subsectors deemed at risk of carbon leakage for the period 2021 to 2030 (1) is to be incorporated into the EEA Agreement.

| (2) | Annex XX to the EEA Agreement should therefore be amended accordingly, |
| --- | --- |

(2)

Annex XX to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following point is inserted after point 21all (Commission Delegated Regulation (EU) 2019/331) of Annex XX to the EEA Agreement:

| ‘21alm. | 32019 D 0708: Commission Delegated Decision (EU) 2019/708 of 15 February 2019 supplementing Directive 2003/87/EC of the European Parliament and of the Council concerning the determination of sectors and subsectors deemed at risk of carbon leakage for the period 2021 to 2030 (OJ L 120, 8.5.2019, p. 20).’ |
| --- | --- |

‘21alm.

32019 D 0708: Commission Delegated Decision (EU) 2019/708 of 15 February 2019 supplementing Directive 2003/87/EC of the European Parliament and of the Council concerning the determination of sectors and subsectors deemed at risk of carbon leakage for the period 2021 to 2030 (OJ L 120, 8.5.2019, p. 20).’

Article 2

The text of Delegated Decision (EU) 2019/708 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.

Article 3

This Decision shall enter into force on 12 December 2020, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.

Done at Brussels, 11 December 2020.

For the EEA Joint Committee

The President

Sabine MONAUNI

---

(1)  
  OJ L 120, 8.5.2019, p. 20.

1

(*1)  No constitutional requirements indicated.

*1

---
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, April 09, 2019. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, April 09, 2019 The Court of Appeals hereby passes the following order A19D0380. CHRISTINE WILLIAMS v. CITY OF DOUGLASVILLE et al. .
Upon consideration of the Application for Discretionary Appeal, it is ordered that it be hereby GRANTED. The Appellant may file a Notice of Appeal within 10 days of the date of this order. The Clerk of Superior Court is directed to include a copy of this order in the record transmitted to the Court of Appeals.
LC NUMBERS: 18CV01865
§ 520.2098 Selegiline. ( a ) *Specifications.* Each tablet contains 2, 5, 10, 15, or 30 milligrams (mg) selegiline hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amounts and indications for use.* ( i ) Administer 1 mg per kilogram (0.45 mg per pound) of body weight once daily for control of clinical signs associated with uncomplicated pituitary-dependent hyperadrenocorticism in dogs.
( ii ) Administer 0.5 to 1.0 mg per kilogram of body weight once daily for the control of clinical signs associated with canine cognitive dysfunction syndrome.
( 2 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28828, May 20, 2014]
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1540 Nitrogen. ( a ) Nitrogen (empirical formula N2, CAS Reg. No. 7727-37-9) is a colorless, odorless, flavorless gas that is produced commercially by the fractionation of liquid air.
( b ) The ingredient must be of a purity suitable for its intended use.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitations other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a propellant, aerating agent, and gas as defined in § 170.3(o)(25) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 57270, Dec. 29, 1983, as amended at 73 FR 8607, Feb. 14, 2008]
<PAGE>   1
 
                                   EXHIBIT 23
 
                       CONSENT OF INDEPENDENT ACCOUNTANTS
 
     We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (No. 2-74896, No. 33-38737 and No. 33-73044) and in the
Prospectus constituting part of the Registration Statement on Form S-3 (No.
33-71030) and in the Prospectus constituting part of the Registration Statement
on Form S-4 (No. 33-65229) of Bell Industries, Inc. of our report dated January
31, 1996 appearing on page 11 of this Form 10-K.
 
PRICE WATERHOUSE LLP
 
Los Angeles, California
March 12, 1996
<Page>

                                                                    EXHIBIT 32.1

                  CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
                           PURSUANT TO 18 U.S.C. 1350
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    I, John P. Saldarelli, Treasurer and Chief Financial Officer (Principal
Financial Officer) of American Property Investors, Inc., the General Partner of
American Real Estate Partners, L.P. (the 'Registrant'), certify that to the best
of my knowledge, based upon a review of the American Real Estate Partners, L.P.
Quarterly Report on Form 10-Q for the period ended September 30, 2003 of the
Registrant (the 'Report'):

        (1) The Report fully complies with the requirements of Section 13(a) or
    15(d) of the Securities Exchange Act of 1934, as amended; and

        (2) The information contained in the Report fairly presents, in all
    material respects, the financial condition and results of operations of the
    Registrant.

                                                 /s/ JOHN P. SALDARELLI
                                           .....................................
                                                     JOHN P. SALDARELLI
                                           TREASURER AND CHIEF FINANCIAL OFFICER
                                             AMERICAN PROPERTY INVESTORS, INC.,
                                                   THE GENERAL PARTNER OF
                                            AMERICAN REAL ESTATE PARTNERS, L.P.

Date: November 14, 2003
* Pursuant to 5 TH C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals

Fifth Circuit 

## FILED April 4, 2007 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 06-51175 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus JOSE ALEJANDRO LUNA-GONZALEZ, also known as Jose A. Luna, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Western District of Texas USDC No. 3:06-CR-378-ALL

-------------------- Before JONES, Chief Judge, and HIGGINBOTHAM and CLEMENT, Circuit Judges.
PER CURIAM: * Appealing the Judgment in a Criminal Case, Jose Alejandro Luna-Gonzalez raises arguments that are foreclosed by AlmendarezTorres v. United States , 523 U.S. 224, 235 (1998), which held that 8 U.S.C. § 1326(b)(2) is a penalty provision and not a separate criminal offense. The Government’s motion for summary affirmance is GRANTED, and the judgment of the district court is
AFFIRMED.
Exhibit 32.2

CERTIFICATION OF CHIEF ACCOUNTING OFFICER

Pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 (18 U.S.C. 1350)

The undersigned, Kevin G. Wills, Executive Vice President of Finance and Chief Accounting Officer of Saks
Incorporated (the Company), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Companys Quarterly Report on Form 10-Q for the quarter ended October 28, 2006, (the
Report).

The undersigned hereby certifies that:



| | 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | -- | ---------------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------

IN WITNESS WHEREOF, the undersigned has executed this certification as of the 6th day of December, 2006.



|                                                                
|----------------------------------------------------------------
|/s/ Kevin G. Wills                                              
|Kevin G. Wills                                                  
|Executive Vice President of Finance and Chief Accounting Officer

A signed original of this written statement required by Section 906 has been provided to Saks Incorporated
and will be retained by Saks Incorporated and furnished to the Securities and Exchange Commission or its staff upon request.
§ 510.410 Corticosteroids for oral, injectable, and ophthalmic use in animals; warnings and labeling requirements. ( a ) The Food and Drug Administration has received reports of side effects associated with the oral, injectable, and ophthalmic use of corticosteroid animal drugs. The use of these drugs administered orally or by injection has resulted in premature parturition when administered during the last trimester of pregnancy. Premature parturition may be followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids used in dogs, rabbits, and rodents during pregnancy have produced cleft palate in offspring. Use in dogs has resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. Drugs subject to this section are required to carry the veterinary prescription legend and are subject to the labeling requirements of § 201.105 of this chapter.
( b ) In view of these potentially serious side effects, the Food and Drug Administration has concluded that the labeling on or within packaged corticosteroid-containing preparations intended for animal use shall bear conspicuously the following warning statement:
*Warning:* Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca.
[49 FR 48535, Dec. 13, 1984]
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 01-7046

DEMETRIOUS ERIC BROWN, a/k/a Denrick Eric

Brown, a/k/a Demmerick Eric Brown,

Plaintiff - Appellant,

versus

RONALD J. ANGELONE, Director; GENE M. JOHNSON,

Deputy Director; REFUS FLEMING, Regional

Director; DAVID GARRAGHTY, Chief Warden; S. J.

AVENT, Administrative Assistant Warden; J. D.

OATHS, Medical Administrator for the Virginia

Department of Corrections; J. CAPPS, Human

Rights Advocate; CHARLES ALLEN, Unit Manager;

B. PHILLIPS, Medical Administrator for (CMS);

ELLA KLUG, Regional Administrator for (CMS);

BETH KENNEDY, Regional Manager for (CMS); MIKE

PFEIFFER, Medical Operation Manager for (CMS);

ANNETTE HOLMES, Medical Administrator for

(CMS); K. HAMLIN, Head Nurse for (CMS); D.

SLOAN, LPN FOR (CMS); C. MANNING, LPN for

(CMS); ROY P. HARRIS, Prison Guard, Lieutenant; VINCENT M. GORE, Doctor for (CMS); M.

VERNON SMITH, Doctor, Health Care Director;

DOCTOR SWETHER; DOCTOR SALIH,

Defendants - Appellees.

Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. Claude M. Hilton, Chief District

Judge. (CA-01-144-AM)

Submitted: August 9, 2001 Decided: August 17, 2001
2

Before NIEMEYER, MOTZ, and GREGORY, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Demetrious Eric Brown, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).

PER CURIAM:

Demetrious Eric Brown appeals the dismissal of his 42 U.S.C.A.

§ 1983 (West Supp. 2000) action alleging indifference to serious

medical need. We dismiss the appeal for lack of jurisdiction

because the order is not appealable. This court may exercise

jurisdiction only over final orders, 28 U.S.C. § 1291 (1994), and

certain interlocutory and collateral orders, 28 U.S.C. § 1292

(1994); Fed. R. Civ. P. 54(b); Cohen v. Beneficial Indus. Loan

Corp., 337 U.S. 541 (1949). The order here appealed is neither a

final order nor an appealable interlocutory or collateral order.

We dismiss the appeal as interlocutory. We dispense with oral

argument because the facts and legal contentions are adequately

presented in the materials before the court and argument would not

aid the decisional process.

DISMISSED
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.69 Butterfly pea flower extract. ( a ) *Identity.* ( 1 ) The color additive butterfly pea flower extract is a dark blue liquid prepared by the aqueous extraction of dried butterfly pea flowers from *Clitoria ternatea.* The extract is further processed by ultrafiltration to remove residues of plant products, followed by concentration and pasteurization. Citric acid may be used to control the pH. The color additive contains anthocyanins as the principal coloring component.
( 2 ) Color additive mixtures for food use made with butterfly pea flower extract may contain only those diluents that are suitable and are listed in this subpart as safe for use in color additive mixtures for coloring foods.
( b ) *Specifications.* Butterfly pea flower extract must conform to the following specifications and must be free from impurities, other than those named, to the extent that such other impurities may be avoided by good manufacturing practice: ( 1 ) pH, not less than 3.0 and not more than 4.5 at 25 °C.
( 2 ) Lead, not more than 1 milligram per kilogram (mg/kg) (1 part per million (ppm)).
( 3 ) Arsenic, not more than 1 mg/kg (1 ppm).
( 4 ) Mercury, not more than 1 mg/kg (1 ppm).
( 5 ) Cadmium, not more than 1 mg/kg (1 ppm).
( c ) *Uses and restrictions.* Butterfly pea flower extract may be safely used for coloring alcoholic beverages, sport and energy drinks, flavored or carbonated water, fruit drinks (including smoothies and grain drinks), carbonated soft drinks (fruit-flavored or juice, ginger ale, and root beer), fruit and vegetable juice, nutritional beverages, chewing gum, teas, coated nuts, liquid coffee creamers (dairy and non-dairy), ice cream and frozen dairy desserts, hard candy, dairy and non-dairy drinks, fruit preparations in yogurts, and soft candy in amounts consistent with good manufacturing practice, except that it may not be used for coloring foods for which standards of identity have been issued under section 401 of the Federal Food, Drug, and Cosmetic Act, unless the use of added color is authorized by such standards.
( d ) *Labeling requirements.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes must conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health and therefore batches are exempt from the certification requirements of section 721(c) of the Federal Food, Drug, and Cosmetic Act.
[86 FR 49233, Sept. 2, 2021]
§ 582.1240 Carbon dioxide. ( a ) *Product.* Carbon dioxide.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
#### § 610.11-610.11a [Reserved]
#### State of Connecticut *v.*John Ryant

Decided July 22, 1969

The defendant having filed a motion that this court review the action of the trial court denying his application that a transcript be furnished without cost and that fees, costs, expenses and security in the appeal from the Superior Court in New Haven County be waived, it is ordered that a transcript be furnished the defendant without cost to him and that the original thereof be placed in the file in the Superior Court; and that, in all other respects, the motion be assigned for hearing on Tuesday, October 7,1969, at 10 a.m.